Terms: = Bone cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
621 results:
1. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
2. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, her2-Negative bone Metastatic Breast cancer.
Magno E; Bussard KM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542380
[TBL] [Abstract] [Full Text] [Related]
3. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV her2-positive Breast cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract] [Full Text] [Related]
4. Surgical Resection of Primary Tumor for bone Metastatic Breast cancer Patients at Initial Presentation.
Kitsuya N; Matsuoka M; Onodera T; Yokota I; Iwasaki K; Suzuki Y; Hamasaki M; Kondo E; Iwasaki N
Anticancer Res; 2024 Apr; 44(4):1591-1601. PubMed ID: 38537990
[TBL] [Abstract] [Full Text] [Related]
5. Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.
Zhang J; Zhang J; Niu X; Zhou Y; Guo Y; Wang Y; Shou F
Sci Rep; 2024 Mar; 14(1):6003. PubMed ID: 38472493
[TBL] [Abstract] [Full Text] [Related]
6. Detection of her2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract] [Full Text] [Related]
7. An Integrated Care Approach to Improve Well-Being in Breast cancer Patients.
Fabi A; Rossi A; Mocini E; Cardinali L; Bonavolontà V; Cenci C; Magno S; Barberi V; Moretti A; Besharat ZM; Iolascon G; Baldari C; Ferretti E; Botticelli A; Paris I; Scambia G; Migliaccio S
Curr Oncol Rep; 2024 Apr; 26(4):346-358. PubMed ID: 38400984
[TBL] [Abstract] [Full Text] [Related]
8. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and her2 positive metastatic salivary duct carcinoma. A case report.
Čavka L; Zakotnik B
J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
[TBL] [Abstract] [Full Text] [Related]
9. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
10. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and her2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Palmieri C; Linden H; Birrell SN; Wheelwright S; Lim E; Schwartzberg LS; Dwyer AR; Hickey TE; Rugo HS; Cobb P; O'Shaughnessy JA; Johnston S; Brufsky A; Tilley WD; Overmoyer B
Lancet Oncol; 2024 Mar; 25(3):317-325. PubMed ID: 38342115
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Breast cancer Complicated by Fibrous Dysplasia That Was Difficult to Differentiate from bone Metastasis].
Makino Y; Otani A; Hikino H; Murata Y; Miura H; Harada A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1465-1467. PubMed ID: 38303309
[TBL] [Abstract] [Full Text] [Related]
12. [A Case of Postoperative Recurrence of Bilateral Breast cancer in Which Stable Disease Condition Was Achieved by Olaparib].
Terakawa H; Kawata C; Kurokawa Y; Ooe Y; Mohri R; Hirata M; Moriyama H; Kinoshita J; Kawashima H; Inaki N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1414-1416. PubMed ID: 38303292
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of Recurrent Gastric cancer with Long-Term Control via Two Resections and Multidisciplinary treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
14. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
15. The poor prognosis of lacrimal gland adenocarcinoma: a clinical study and literature review.
Liu R; Ren T; Li J; Wang N; Xu L; Guo Q; Zhang H; Ma J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):26. PubMed ID: 38263473
[TBL] [Abstract] [Full Text] [Related]
16. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
[TBL] [Abstract] [Full Text] [Related]
17. Association of metastatic pattern in breast cancer with tumor and patient-specific factors: a nationwide autopsy study using artificial intelligence.
Kazemzadeh F; Snoek JAA; Voorham QJ; van Oijen MGH; Hugen N; Nagtegaal ID
Breast Cancer; 2024 Mar; 31(2):263-271. PubMed ID: 38133738
[TBL] [Abstract] [Full Text] [Related]
18. The Future of her2-Targeted treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
19. Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer.
Schlam I; Giordano A; Tolaney SM
Expert Opin Drug Saf; 2023; 22(12):1149-1156. PubMed ID: 37994878
[TBL] [Abstract] [Full Text] [Related]
20. A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent cancer Cells.
Calvo V; Zheng W; Adam-Artigues A; Staschke KA; Huang X; Cheung JF; Nobre AR; Fujisawa S; Liu D; Fumagalli M; Surguladze D; Stokes ME; Nowacek A; Mulvihill M; Farias EF; Aguirre-Ghiso JA
Clin Cancer Res; 2023 Dec; 29(24):5155-5172. PubMed ID: 37982738
[TBL] [Abstract] [Full Text] [Related]
[Next]
